Technical Analysis for ARDS - Aridis Pharmaceuticals Inc.

Grade Last Price % Change Price Change
D 0.08 -6.25% -0.01
ARDS closed down 6.25 percent on Monday, March 18, 2024, on 1.38 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to find support at its 50 day moving average.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Down

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
50 DMA Support Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
NR7 Range Contraction 0.00%
BB Squeeze Started Range Contraction 0.00%
Gapped Down Weakness 0.00%
20 DMA Support Bullish -6.25%
Upper Bollinger Band Walk Strength -6.25%
BB Squeeze Ended Range Expansion -6.25%
Upper Bollinger Band Touch Strength -6.25%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 10 hours ago
60 Minute Opening Range Breakdown about 11 hours ago
20 DMA Resistance about 11 hours ago
Fell Below 20 DMA about 11 hours ago
10 DMA Support about 12 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Aridis Pharmaceuticals Inc. Description

Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs), to treat infections. mAbs represents treatment approach that enables the human immune system to fight infections and are designed to overcome the deficiencies associated with current therapies, such as rise in drug resistance, short duration of response, negative impact on the human microbiome, and lack of differentiation among the treatment alternatives. Its product pipeline comprises of human mAbs targeting specific pathogens associated with bacterial infections, primarily hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). Its lead product candidate, AR-301 targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus, a common pathogen associated with HAP and VAP. Its AR-101 (Aerumab) is a fully human immunoglobulin M, mAb targeting P. aeruginosa serotype O11.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Immune System Immunotherapy Infectious Diseases Antibodies Monoclonal Antibodies Monoclonal Antibody Infection Bacterial Infections Bacterial Disease Staphylococcus Aureus Human Monoclonal Antibodies Pathogenic Bacteria Drug Resistance Pneumonia Pseudomonas Aeruginosa Targeted Immunotherapy Immunoglobulin M

Is ARDS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 0.5395
52 Week Low 0.05
Average Volume 111,519
200-Day Moving Average 0.13
50-Day Moving Average 0.07
20-Day Moving Average 0.08
10-Day Moving Average 0.08
Average True Range 0.01
RSI (14) 50.25
ADX 49.56
+DI 15.95
-DI 5.18
Chandelier Exit (Long, 3 ATRs) 0.06
Chandelier Exit (Short, 3 ATRs) 0.09
Upper Bollinger Bands 0.08
Lower Bollinger Band 0.07
Percent B (%b) 0.39
BandWidth 15.47
MACD Line 0.00
MACD Signal Line 0.00
MACD Histogram 0.0002
Fundamentals Value
Market Cap 3.34 Million
Num Shares 44.6 Million
EPS -0.16
Price-to-Earnings (P/E) Ratio -0.47
Price-to-Sales 0.14
Price-to-Book 5.40
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.08
Resistance 3 (R3) 0.08 0.08 0.08
Resistance 2 (R2) 0.08 0.08 0.08 0.08
Resistance 1 (R1) 0.08 0.08 0.08 0.08 0.08
Pivot Point 0.08 0.08 0.08 0.08 0.08
Support 1 (S1) 0.07 0.07 0.07 0.07 0.07
Support 2 (S2) 0.07 0.07 0.07 0.07
Support 3 (S3) 0.07 0.07 0.07
Support 4 (S4) 0.07